TX-MAVENIR/XILINX
13.4.2021 15:02:05 CEST | Business Wire | Press release
Mavenir, the industry’s only end-to-end cloud-native Network Software Provider and a leader in accelerating software network transformation for communications service providers (CSPs), and Xilinx, Inc. (NASDAQ: XLNX), the leader in adaptive computing, announced today the companies are collaborating to bring to market a unified 4G/5G O-RAN massive MIMO (mMIMO) portfolio to enable Open RAN deployments. The first mMIMO 64TRX joint solution is expected to be available in Q4 2021.
Working together, the two companies have successfully completed end-to-end integration of a first-generation mMIMO solution using Open RAN principles. Held at the Mavenir Lab in Bangalore, India, the integration covered multiple deployment scenarios and was evaluated by six CSPs, all leading global operators. Mavenir delivered the Virtualized RAN (vRAN) support for mMIMO, including Core Network, CU and DU, with Xilinx providing the Category B O-RAN Radio Unit.
“This integration demonstrates an efficient Open RAN massive MIMO solution to achieve diversification of the telecommunications supply chain,” says Pardeep Kohli, President and CEO, Mavenir. “This is an important milestone in the delivery of open and interoperable interfaces enabling the deployment of mMIMO in high density, high mobile traffic metro areas.”
“We were early proponents of Open RAN technology along with Mavenir and actively led in standards development in the industry through many field trials around the world,” said Liam Madden, executive vice president and general manager, Wired and Wireless Group at Xilinx. “With the investment we have done on our market-leading wireless radio technology and massive MIMO R&D, we are excited to collaborate with Mavenir to bring our collective technology and radio system expertise together that will accelerate the deployment of market leading 5G O-RAN massive MIMO radio solutions.”
With history of leadership success in various 4G and 5G network deployments worldwide, the companies are jointly developing the next generation of mMIMO products which will bring the world’s first O-RAN compliant 64TRX mMIMO products that support up to 400MHz instantaneous bandwidth in a compact form factor. Mavenir's vRAN software supports Multi-User MIMO with up to 16 layers, advanced receiver algorithms, full digital beamforming - all running on Mavenir's open and flexible cloud-native platform, as well as on other cloud platforms.
These products will leverage Xilinx’s technology platform including RFSoC DFE and Versal AI for advanced beamforming, delivering a fully integrated hardware and software O-RAN compliant mMIMO solution.
“5G Open RAN has significant momentum in the market with ABI Research forecasting network vendor spending to reach $10 billion by 2026-27 and then surpass traditional RAN at $30 billion by 2030,” said Dimitris Mavrakis, senior research director of 5G at ABI Research. “As Mavenir and Xilinx continue to work together to accelerate O-RAN-based massive MIMO adoption, their solutions will be well-timed to serve this high-growth market with the higher spectral efficiency, performance, power efficiency and cost needed as 5G demand intensifies.”
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
About Xilinx:
Xilinx, Inc. develops highly flexible and adaptive processing platforms that enable rapid innovation across a variety of technologies - from the cloud, to the edge, to the endpoint. Xilinx is the inventor of the FPGA and Adaptive SoCs (including our Adaptive Compute Acceleration Platform, or ACAP), designed to deliver the most dynamic computing technology in the industry. We collaborate with our customers to create scalable, differentiated and intelligent solutions that enable the adaptable, intelligent and connected world of the future. For more information, visit xilinx.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005187/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 15:15:00 CEST | Press release
NVentures, ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures join CapitalG, a16z, Menlo Ventures, and others in backing the high-growth AI infrastructure startup OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leadi
Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 15:00:00 CEST | Press release
Xsolla Adds New Features For Creators, Community Leader Experience, And Distinct Channels For Emerging Markets Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release
First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 14:00:00 CEST | Press release
Company will demonstrate how high-quality, well-characterized biospecimens are critical to the success of both new approach methodologies (NAMs) and traditional studies BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom